Skip to main content
UniHealth
Find my savings

Doctor search

Amit G Pandya, MD

Dermatology · Mountain View

NPI 1245299379

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
14
2 carriers
Office
1

Offices

1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group

Looking this up.

Plans that list them

14 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Pandya’s office at (650) 691-6174 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

14 of 14 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Sutter Advantage +More (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence C166658 · Current

Licensed to practise in California · since 2019 · expires 2027-11-30 · University of Texas Southwestern Medical School at Dallas.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

State licence records

1 licence

  • Texas H1013Physician License · since 1986 · expires 2023-02-28
    Canc Non-RenewalNo board action on this licenceCheck it with the state

We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.

Original Medicare doctor bills

$28,694

Medicare paid this office $28,694 for 101 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Application of ultraviolet light to skin34$13,709$26
Return visit (30+ min)54$8,946$113
Short return visit (20+ min)25$2,322$73

Procedures Medicare counted

Procedure volume Medicare published
Skin biopsy1-10None

Who their Medicare patients are

101 Original Medicare patients in 2024. Average age 72 · Women 65% · Also on Medicaid 11% · Health risk score 0.71. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 50% · Diabetes 25% · Coronary heart disease 16% · Chronic kidney disease 11% · Depression 11%.

The office billed $113,356, Medicare allowed $39,312 and paid $28,694; for 665 services of 12 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024101665720.71$113,356$28,694
202381609720.92$102,191$26,646
2022127734750.91$109,516$31,503
202195552751.09$97,294$28,732
202062275730.71$41,773$12,187
2019241780741.41$142,122$31,538
20183724,042731.22$310,685$68,790
20173881,524731.34$253,222$64,167
20164251,731721.31$277,276$66,722
20153661,603721.25$257,375$60,030
20144281,563721.26$253,334$62,062
20134461,926721.31$296,584$71,874

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 3 services

Original Medicare services billed in 2023
Application of ultraviolet light to skin29$11,715$25
Return visit (30+ min)24$4,417$119
Short return visit (20+ min)36$4,140$78

2022: 7 services

Original Medicare services billed in 2022
Application of ultraviolet light to skin18$10,072$25
Short return visit (20+ min)66$5,944$69
Return visit (30+ min)31$4,905$117
New patient visit (30+ min)17$1,750$103
Destruction of precancer skin growth, 1 growth27$1,690$55
Biopsy of related skin growth, first growth14$1,436$103
Destruction of precancer skin growth, 2-14 growths24$718$7

2021: 8 services

Original Medicare services billed in 2021
Application of ultraviolet light to skin20$6,794$25
Short return visit (20+ min)43$5,564$86
Return visit (30+ min)16$2,100$124
Destruction of skin growth, 1-14 growths14$1,809$113
Short return visit24$1,201$48
New patient visit (30+ min)14$981$70
Destruction of precancer skin growth, 1 growth15$965$44
Destruction of precancer skin growth, 2-14 growths12$365$7

2020: 3 services

Original Medicare services billed in 2020
Application of ultraviolet light to skin12$4,084$25
Short return visit (20+ min)22$2,122$71
Short return visit12$451$35

2019: 11 services

Original Medicare services billed in 2019
Therapy procedure using ultraviolet radiation with tar or petroleum jelly application23$7,462$90
Short return visit (20+ min)137$7,383$46
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)11$3,927None
Destruction of precancer skin growth, 1 growth68$2,774$39
Destruction of skin growth, 1-14 growths26$2,110$78
New patient visit (30+ min)17$1,070$63
Destruction of precancer skin growth, 2-14 growths56$977$4
Application of light to destroy precancer skin growth11$941$78
Biopsy of related skin growth, first growth17$890$52
Short return visit (20+ min)17$651$36
Short return visit23$649$25

2018: 13 services

Original Medicare services billed in 2018
Therapy procedure using ultraviolet radiation with tar or petroleum jelly application33$16,574$90
Short return visit (20+ min)194$14,309$51
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)15$7,543None
Destruction of skin growth, 1-14 growths53$5,472$87
Destruction of precancer skin growth, 1 growth103$5,362$40
Application of light to destroy precancer skin growth29$2,613$79
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg13$2,506None
Biopsy of single growth of skin and/or tissue32$2,324$70
Destruction of precancer skin growth, 2-14 growths82$1,753$4
Short return visit (20+ min)48$1,712$35
New patient visit (30+ min)29$1,706$59
Short return visit40$1,422$28
Short return visit12$223$19

2017: 13 services

Original Medicare services billed in 2017
Short return visit (20+ min)207$15,766$51
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)24$13,595None
Therapy procedure using ultraviolet radiation with tar or petroleum jelly application26$6,632$54
Destruction of precancer skin growth, 1 growth110$5,855$40
Destruction of skin growth, 1-14 growths49$4,487$79
Application of light to destroy precancer skin growth25$3,349$105
Biopsy of single growth of skin and/or tissue39$2,846$68
Short return visit65$2,545$31
New patient visit (30+ min)35$2,405$69
Destruction of precancer skin growth, 2-14 growths89$1,832$4
Short return visit (20+ min)31$1,259$35
Biopsy of single growth of skin and/or tissue12$474$39
Short return visit15$304$19

2016: 13 services

Original Medicare services billed in 2016
Short return visit (20+ min)233$17,497$49
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)17$8,028None
Destruction of precancer skin growth, 1 growth121$6,275$38
Biopsy of single growth of skin and/or tissue72$6,121$74
Therapy procedure using ultraviolet radiation with tar or petroleum jelly application19$5,459$57
Destruction of skin growth, 1-14 growths38$3,583$81
New patient visit (30+ min)38$2,906$76
Short return visit (20+ min)62$2,758$38
Short return visit72$2,511$30
Application of light to destroy precancer skin growth17$2,266$99
Destruction of precancer skin growth, 2-14 growths90$2,231$4
Biopsy of each additional growth of skin and/or tissue13$495$26
Short return visit11$200$17

2015: 13 services

Original Medicare services billed in 2015
Short return visit (20+ min)211$16,073$49
Biopsy of single growth of skin and/or tissue66$5,643$70
Destruction of skin growth, 1-14 growths50$5,504$83
Destruction of precancer skin growth, 1 growth105$5,484$38
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)12$3,969None
Short return visit58$2,434$31
New patient visit (30+ min)30$2,277$76
Destruction of precancer skin growth, 2-14 growths78$1,860$4
Short return visit (20+ min)44$1,692$32
Application of light to destroy precancer skin growth12$1,288$92
Biopsy of each additional growth of skin and/or tissue23$853$26
New patient visit (30+ min)14$790$56
Biopsy of single growth of skin and/or tissue14$455$32

2014: 14 services

Original Medicare services billed in 2014
Short return visit (20+ min)244$18,644$49
Destruction of precancer skin growth, 1 growth116$6,693$46
Biopsy of single growth of skin and/or tissue68$6,201$72
Destruction of skin growth, 1-14 growths60$5,993$81
Destruction of precancer skin growth, 2-14 growths93$3,291$8
Short return visit (20+ min)69$3,073$38
Therapy procedure using ultraviolet radiation with tar or petroleum jelly application14$2,812$55
New patient visit (30+ min)28$2,221$79
Short return visit44$1,586$28
Application of light to destroy precancer skin growth11$1,259$97
Biopsy of single growth of skin and/or tissue17$545$32
Biopsy of each additional growth of skin and/or tissue13$487$26
Destruction of precancer skin growth, 1 growth11$461$42
Short return visit19$336$18

2013: 17 services

Original Medicare services billed in 2013
Short return visit (20+ min)262$23,116$50
Destruction of precancer skin growth, 1 growth142$9,547$50
Biopsy of single growth of skin and/or tissue67$6,361$79
Destruction of skin growth, 1-14 growths47$4,536$86
Destruction of precancer skin growth, 2-14 growths109$3,173$5
Therapy procedure using ultraviolet radiation with tar or petroleum jelly application17$3,150$57
Return visit (30+ min)20$2,995$75
Short return visit (20+ min)73$2,946$36
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)12$2,746None
New patient visit (30+ min)23$1,858$81
Short return visit45$1,779$28
Application of light to destroy precancer skin growth12$1,538$103
Biopsy of each additional growth of skin and/or tissue18$747$26
New patient visit (30+ min)12$651$54
New patient visit (15+ min)16$502$31
Biopsy of single growth of skin and/or tissue14$442$29
Short return visit12$251$19

Drugs they prescribed that Part D paid

$100,423

Pharmacies billed $100,423 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 142) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

67 generic and 75 brand-name prescriptions · $100,423 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Opzelura39$77,566$1,989
Tranexamic Acid43$3,433$80
Tacrolimus16$2,141$134

Year by year

Part D prescribing by year
2024142500% (0)53%$100,423
2023140470% (0)39%$95,527
2022121580% (0)19%$44,992
2021108440% (0)None$4,577
202066350% (0)None$2,416
20194621390% (0)15%$130,099
20186511870% (0)14%$176,848
20175971840% (0)11%$113,309
2016590198None9%$157,436
20156371820% (0)14%$189,214
20148452250% (0)None$176,831
2013979200NoneNone$484,469

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 4 drugs

Part D drugs prescribed in 2023
Opzelura33$87,479$2,651
Tacrolimus12$2,561$213
Tranexamic Acid24$1,700$71
Triamcinolone Acetonide17$266$16

2022: 2 drugs

Part D drugs prescribed in 2022
Opzelura20$40,522$2,026
Triamcinolone Acetonide25$301$12

2021: 2 drugs

Part D drugs prescribed in 2021
Triamcinolone Acetonide20$358$18
Betamethasone Diprop Augmented12$167$14

2019: 15 drugs

Part D drugs prescribed in 2019
Clobetasol Propionate31$2,377$77
Mycophenolate Mofetil13$1,550$119
Desonide13$1,491$115
Doxepin25$1,457$58
Fluocinonide19$1,303$69
Betamethasone Dipropionate19$1,259$66
Doxycycline Hyclate12$1,201$100
Tranexamic Acid12$1,192$99
Betamethasone Diprop Augmented11$1,083$98
Valacyclovir13$994$76
Triamcinolone Acetonide41$819$20
Cefadroxil12$331$28
Ketoconazole23$316$14
Hydroxyzine26$295$11
Mupirocin16$262$16

2018: 18 drugs

Part D drugs prescribed in 2018
Clobetasol Propionate81$8,565$106
Fluocinonide40$3,226$81
Triamcinolone Acetonide73$2,216$30
Fluorouracil13$1,987$153
Doxycycline Hyclate18$1,812$101
Betamethasone Dipropionate25$1,661$66
Mycophenolate Mofetil16$1,198$75
Tretinoin15$1,181$79
Betamethasone Diprop Augmented24$1,143$48
Desonide13$1,045$80
Mupirocin37$615$17
Azathioprine15$613$41
Doxycycline Monohydrate13$484$37
Ketoconazole31$467$15
Minocycline13$312$24
Dexamethasone16$216$13
Cefadroxil12$178$15
Hydroxyzine12$81$7

2017: 20 drugs

Part D drugs prescribed in 2017
Clobetasol Propionate84$13,282$158
Doxycycline Hyclate20$2,945$147
Fluocinonide29$2,450$84
Desonide15$2,152$143
Fluorouracil15$1,961$131
Tretinoin11$1,175$107
Azathioprine25$969$39
Doxepin18$962$53
Betamethasone Dipropionate12$892$74
Methotrexate14$750$54
Triamcinolone Acetonide48$723$15
Valacyclovir18$523$29
Mupirocin42$483$11
Ketoconazole36$433$12
Doxycycline Monohydrate11$404$37
Hydroxyzine22$371$17
Minocycline12$241$20
Acyclovir15$144$10
Prednisone11$104$9
Terbinafine11$81$7

2016: 19 drugs

Part D drugs prescribed in 2016
Clobetasol Propionate107$24,258$227
Acitretin16$10,497$656
Fluocinonide16$2,721$170
Doxycycline Hyclate24$1,913$80
Fluorouracil15$1,735$116
Desonide13$1,715$132
Doxepin36$1,484$41
Metronidazole13$1,252$96
Dapsone14$1,235$88
Imiquimod11$1,156$105
Triamcinolone Acetonide51$940$18
Azathioprine16$729$46
Minocycline20$613$31
Acyclovir22$553$25
Methotrexate13$443$34
Ketoconazole29$427$15
Mupirocin26$285$11
Hydroxyzine19$232$12
Dexamethasone11$72$7

2015: 15 drugs

Part D drugs prescribed in 2015
Clobetasol Propionate85$17,850$210
Fluocinonide29$3,434$118
Desonide22$2,873$131
Triamcinolone Acetonide69$1,665$24
Dapsone23$1,380$60
Minocycline25$1,318$53
Azathioprine24$1,188$49
Metronidazole12$1,160$97
Ketoconazole39$849$22
Hydroxyzine34$675$20
Doxepin17$485$29
Mupirocin35$379$11
Acyclovir21$359$17
Prednisone20$191$10
Terbinafine11$140$13

2014: 22 drugs

Part D drugs prescribed in 2014
Valchlor11$36,867$3,352
Clobetasol Propionate140$15,877$113
Desonide34$7,068$208
Intron A13$6,666$513
Doxycycline Hyclate26$4,323$166
Mycophenolate Mofetil21$2,774$132
Triamcinolone Acetonide87$2,442$28
Fluorouracil11$1,920$175
Valacyclovir17$1,916$113
Fluocinonide31$1,634$53
Metronidazole13$1,454$112
Dapsone24$1,344$56
Azathioprine21$1,099$52
Hydroxyzine34$856$25
Methotrexate15$789$53
Minocycline22$670$30
Ketoconazole35$534$15
Mupirocin38$471$12
Prednisone34$332$10
Acyclovir23$323$14
Fluconazole12$247$21
Doxepin12$189$16

2013: 22 drugs

Part D drugs prescribed in 2013
Targretin25$332,480$13,299
Intron A43$39,903$928
Mycophenolate Mofetil44$6,791$154
Imiquimod18$6,771$376
Desonide30$4,722$157
Clobetasol Propionate103$3,795$37
Doxycycline Hyclate24$3,421$143
Methotrexate29$2,913$100
Valacyclovir29$2,419$83
Fluorouracil11$2,066$188
Dapsone24$1,899$79
Fluocinonide42$1,635$39
Metronidazole15$1,538$103
Triamcinolone Acetonide70$1,393$20
Azathioprine28$1,054$38
Minocycline38$1,011$27
Hydroxyzine45$976$22
Mupirocin54$938$17
Ketoconazole37$619$17
Prednisone64$531$8
Acyclovir13$347$27
Doxepin18$276$15

Money from drug and device companies

$10,088 in 2025

Industry payments by year
2025921$9,867$10,088
2024712$28,825$28,933
2023630$33,536$36,245
202238$13,381$13,444
2021412$46,637$46,637
2020420$69,484$69,626
2019322$113,079$115,904

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Eli Lilly andEbglyss$5,200
2 payments
  • Consulting for Ebglyss · 2025-12-15 · $4,000
  • Consulting for Ebglyss · 2025-07-21 · $1,200
Takeda Pharmaceuticals U.S.A.None$2,400
1 payment
  • Consulting · 2025-07-09 · $2,400
IncyteOpzelura$1,667
7 payments
  • Meals for Opzelura · 2025-12-17 · $1
  • Meals for Opzelura · 2025-12-17 · $19
  • Meals for Opzelura · 2025-12-02 · $4
  • Meals for Opzelura · 2025-12-02 · $17
  • Consulting · 2025-08-05 · $1,600
  • Meals for Opzelura · 2025-02-05 · $2
  • Meals for Opzelura · 2025-02-05 · $24
AbbvieRinvoq$667
1 payment
  • Consulting for Rinvoq · 2025-09-15 · $667
Novartis PharmaceuticalsCosentyx$48
2 payments
  • Meals for Rhapsido · 2025-10-09 · $21
  • Meals for Cosentyx · 2025-01-28 · $27
STRATA Skin SciencesXtrac$45
2 payments
  • Meals for Xtrac · 2025-07-08 · $19
  • Meals for Xtrac · 2025-04-21 · $26
See all 21 published payments
Every published payment
IncyteMeals · 2025-12-17Opzelura$1
IncyteMeals · 2025-12-17Opzelura$19
Eli Lilly andConsulting · 2025-12-15Ebglyss$4,000
IncyteMeals · 2025-12-02Opzelura$4
IncyteMeals · 2025-12-02Opzelura$17
Novartis PharmaceuticalsMeals · 2025-10-09Rhapsido$21
AbbvieConsulting · 2025-09-15Rinvoq$667
Arcutis BiotherapeuticsMeals · 2025-08-27Zoryve$19
Lilly USAMeals · 2025-08-05Taltz$5
Lilly USAMeals · 2025-08-05Taltz$5
Lilly USAMeals · 2025-08-05Taltz$5
Lilly USAMeals · 2025-08-05Taltz$4
IncyteConsulting · 2025-08-05None$1,600
Eli Lilly andConsulting · 2025-07-21Ebglyss$1,200
Takeda Pharmaceuticals U.S.A.Consulting · 2025-07-09None$2,400
STRATA Skin SciencesMeals · 2025-07-08Xtrac$19
Janssen BiotechMeals · 2025-05-06Tremfya$25
STRATA Skin SciencesMeals · 2025-04-21Xtrac$26
IncyteMeals · 2025-02-05Opzelura$2
IncyteMeals · 2025-02-05Opzelura$24
Novartis PharmaceuticalsMeals · 2025-01-28Cosentyx$27
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $28,933

Payments by company in 2024
AbbvieRinvoq$16,800
2 payments
  • Consulting for Rinvoq · 2024-06-11 · $1,600
  • Consulting for Rinvoq · 2024-03-12 · $15,200
Eli Lilly andOlumiant$6,400
2 payments
  • Consulting · 2024-04-02 · $2,400
  • Consulting for Olumiant · 2024-03-28 · $4,000
IncyteOpzelura$5,625
2 payments
  • Consulting for Opzelura · 2024-03-28 · $1,500
  • Consulting for Opzelura · 2024-03-21 · $4,125
Novartis PharmaceuticalsCosentyx$50
2 payments
  • Meals for Cosentyx · 2024-11-05 · $23
  • Meals for Cosentyx · 2024-10-01 · $27
E.R. Squibb & Sons L.L.C.Sotyktu$23
1 payment
  • Meals for Sotyktu · 2024-12-10 · $23
Arcutis BiotherapeuticsZoryve$22
1 payment
  • Meals for Zoryve · 2024-09-09 · $22
PfizerEucrisa$13
2 payments
  • Meals for Eucrisa · 2024-05-13 · $6
  • Meals for Eucrisa · 2024-03-28 · $7

2023: $36,245

Payments by company in 2023
IncyteNone$21,196
21 payments
  • Paid to speak or teach · 2023-12-21 · $3,000
  • Meals · 2023-10-17 · $18
  • Paid to speak or teach · 2023-10-02 · $3,750
  • Meals · 2023-07-05 · $68
  • Consulting · 2023-05-03 · $3,500
  • Meals · 2023-03-20 · $51
  • Meals · 2023-02-10 · $17
  • Meals · 2023-02-10 · $20
  • Meals · 2023-02-10 · $26
  • Meals · 2023-02-10 · $9
  • Travel · 2023-02-10 · $120
  • Consulting · 2023-02-10 · $4,200
  • Consulting · 2023-02-10 · $2,800
  • Consulting · 2023-02-10 · $495
  • Meals · 2023-02-09 · $66
  • Meals · 2023-02-09 · $125
  • Travel · 2023-02-09 · $840
  • Travel · 2023-02-09 · $394
  • Travel · 2023-02-09 · $259
  • Consulting · 2023-02-09 · $1,400
  • Education · 2023-02-03 · $38
Eli Lilly andNone$6,971
3 payments
  • Consulting · 2023-12-12 · $6,400
  • Travel · 2023-12-08 · $228
  • Travel · 2023-12-08 · $344
AbbvieRinvoq$4,908
2 payments
  • Consulting for Rinvoq · 2023-04-13 · $4,900
  • Meals for Rinvoq · 2023-03-20 · $8
PfizerEucrisa$1,804
2 payments
  • Meals for Eucrisa · 2023-03-20 · $4
  • Consulting · 2023-02-10 · $1,800
Boehringer Ingelheim International GmbHNone$1,290
1 payment
  • Consulting · 2023-10-19 · $1,290
Avita Medical AmericasRecell$75
1 payment
  • Meals for Recell · 2023-05-04 · $75

2022: $13,444

Payments by company in 2022
AbbvieRinvoq$7,986
4 payments
  • Consulting for Rinvoq · 2022-08-19 · $2,300
  • Consulting · 2022-07-15 · $4,025
  • Consulting for Rinvoq · 2022-05-04 · $1,650
  • Meals · 2022-03-25 · $11
IncyteOpzelura$3,859
3 payments
  • Meals for Opzelura · 2022-11-04 · $53
  • Consulting · 2022-05-09 · $2,400
  • Paid to speak or teach · 2022-01-24 · $1,406
Eli Lilly andNone$1,600
1 payment
  • Paid to speak or teach · 2022-07-20 · $1,600

2021: $46,637

Payments by company in 2021
IncyteNone$22,122
7 payments
  • Paid to speak or teach · 2021-12-15 · $650
  • Paid to speak or teach · 2021-08-31 · $4,286
  • Paid to speak or teach · 2021-08-31 · $4,286
  • Consulting · 2021-06-21 · $2,100
  • Consulting · 2021-04-19 · $5,500
  • Consulting · 2021-04-19 · $2,000
  • Consulting · 2021-01-15 · $3,300
AbbVieRinvoq$13,200
1 payment
  • Consulting for Rinvoq · 2021-06-25 · $13,200
PfizerNone$8,565
3 payments
  • Consulting · 2021-08-30 · $1,100
  • Consulting · 2021-04-05 · $1,925
  • Consulting · 2021-03-25 · $5,540
Zerigo HealthClarify Medical$2,750
1 payment
  • Consulting for Clarify Medical · 2021-05-03 · $2,750

2020: $69,626

Payments by company in 2020
PfizerNone$32,900
8 payments
  • Consulting · 2020-12-23 · $3,300
  • Consulting · 2020-11-23 · $1,775
  • Consulting · 2020-11-17 · $500
  • Consulting · 2020-10-21 · $5,500
  • Consulting · 2020-07-13 · $3,025
  • Consulting · 2020-05-25 · $4,400
  • Consulting · 2020-04-27 · $4,400
  • Consulting · 2020-01-27 · $10,000
IncyteNone$29,874
6 payments
  • Paid to speak or teach · 2020-10-29 · $1,607
  • Consulting · 2020-09-03 · $15,600
  • Paid to speak or teach · 2020-06-02 · $5,158
  • Paid to speak or teach · 2020-06-02 · $5,158
  • Paid to speak or teach · 2020-05-14 · $743
  • Paid to speak or teach · 2020-03-20 · $1,608
Clarify MedicalClarify Home Light Therapy System$3,850
2 payments
  • Consulting for Clarify Home Light Therapy System · 2020-10-19 · $1,650
  • Consulting for Clarify Home Light Therapy System · 2020-07-12 · $2,200
Ortho Dermatologics a division of Bausch Health USArazlo$3,002
4 payments
  • Consulting for Arazlo · 2020-01-30 · $2,860
  • Meals for Arazlo · 2020-01-27 · $76
  • Meals for Arazlo · 2020-01-27 · $47
  • Meals for Arazlo · 2020-01-27 · $20

2019: $115,904

Payments by company in 2019
PfizerNone$71,250
14 payments
  • Consulting · 2019-12-16 · $10,000
  • Consulting · 2019-11-25 · $10,000
  • Consulting · 2019-11-25 · $10,000
  • Consulting · 2019-11-18 · $10,000
  • Consulting · 2019-11-18 · $10,000
  • Consulting · 2019-09-30 · $14,800
  • Consulting · 2019-03-27 · $1,000
  • Consulting · 2019-03-04 · $4,000
  • Meals · 2019-03-01 · $38
  • Travel · 2019-02-28 · $108
  • Travel · 2019-01-26 · $447
  • Travel · 2019-01-26 · $303
  • Travel · 2019-01-26 · $262
  • Meals · 2019-01-26 · $292
Clarify MedicalClarify Home Light Therapy System$30,000
1 payment
  • Consulting for Clarify Home Light Therapy System · 2019-11-08 · $30,000
IncyteNone$14,654
7 payments
  • Travel · 2019-11-07 · $799
  • Meals · 2019-11-07 · $101
  • Travel · 2019-11-07 · $277
  • Travel · 2019-11-07 · $190
  • Meals · 2019-10-11 · $8
  • Consulting · 2019-09-26 · $11,000
  • Paid to speak or teach · 2019-09-06 · $2,279

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Incyte Corporation · A Double Blind, Randomized, Dose Ranging Study of Incb018424 Phosphate Cream in Subjects With Vitiligo · 2019Their institution$92,891
PFIZER INC. · A Phase 2b Randomized Doubleblind Placebocontrolled Multicenter Doseranging Study To Evaluate the Efficacy and Safety Profile of Pf06651600 With A Partially Blinded Extension Period To Evaluate the Efficacy and Safety of Pf06651600 and Pf06700841 in Subjects With Active Nonsegmental Vitiligo · 2019Their institution$78,969
Avita Medical Americas, Llc · A Prospective Post-Market Clinical Study Investigating Repigmentation of Stable Vitiligo Lesions Using Spray-on Skin Cells · 2024Their institution$53,714
PFIZER INC. · A Phase 2b Randomized Doubleblind Placebocontrolled Multicenter Doseranging Study To Evaluate the Efficacy and Safety Profile of Pf06651600 With A Partially Blinded Extension Period To Evaluate the Efficacy and Safety of Pf06651600 and Pf06700841 in Subjects With Active Nonsegmental Vitiligo · 2020Their institution$51,373
Incyte Corporation · A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo · 2023Their institution$48,194
Aclaris Therapeutics, Inc. · An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of Ati-502 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo · 2019Their institution$38,713
Incyte Corporation · A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo · 2024Their institution$28,696
Incyte Corporation · A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo · 2024Their institution$26,040
Incyte Corporation · A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo · 2025Their institution$22,125
PFIZER INC. · Ritlecitinib Clinical Publication Program · 2022This clinician$17,160
PFIZER INC. · Ritlecitinib Clinical Publication Program · 2021This clinician$16,360
Avita Medical Americas, LLC · Ctp010 Additional Vitiligo Study · 2025Their institution$15,269
Incyte Corporation · A Phase 2, Open Label, Single Agent, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Metastatic Or Surgically Unresectable Urothelial Carcinoma Harboring Fgf/Fgfr Alterations · 2020Their institution$15,158
Avita Medical Americas, Llc · A Prospective Post-Market Clinical Study Investigating Repigmentation of Stable Vitiligo Lesions Using Spray-on Skin™ Cells · 2024Their institution$9,279
Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 1 (True-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2022Their institution$9,270
Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 2 (True-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2022Their institution$9,270
Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 1 (True-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2023Their institution$7,707
PFIZER INC. · Ritlecitinib Clinical Publication Program · 2025This clinician$6,290
Incyte Corporation · A Double Blind, Randomized, Dose Ranging Study of Incb018424 Phosphate Cream in Subjects With Vitiligo · 2021Their institution$5,890
Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 2 (True-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2023Their institution$5,004
Incyte Corporation · A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study To Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo · 2023Their institution$4,930
Incyte Corporation · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of Incb054707 Followed By An Extension Period in Participants With Vitiligo · 2023Their institution$4,856
PFIZER INC. · Ritlecitinib Clinical Publication Program · 2024This clinician$4,470
ABBVIE INC. · Rinvoq · 2021This clinician$4,400
Incyte Corporation · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of Incb054707 Followed By An Extension Period in Participants With Vitiligo · 2024Their institution$3,333
ABBVIE INC. · A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study To Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy · 2024This clinician$3,159
Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 1 (True-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2025Their institution$2,550
Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 2 (True-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2021Their institution$2,540
Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 1 (True-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2021Their institution$2,540
Incyte Corporation · A Double Blind, Randomized, Dose Ranging Study of Incb018424 Phosphate Cream in Subjects With Vitiligo · 2023Their institution$2,500
Incyte Corporation · A Double Blind, Randomized, Dose Ranging Study of Incb018424 Phosphate Cream in Subjects With Vitiligo · 2022Their institution$1,371
Incyte Corporation · A Phase 2 Study of Ruxolitnib Cream for the Treatment of Patients With Vitiligo · 2019Their institution$1,023
PFIZER INC. · Ritlecitinib Clinical Publication Program · 2020This clinician$660
Incyte Corporation · A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo · 2023Their institution$548
PFIZER INC. · Litfulo Clinical Publication Program · 2024This clinician$330

Professional record

NPI
1245299379
Licence
CA C166658, TX H1013California C166658: Current · expires 2027-11-30Texas H1013: Canc Non-Renewal
Trained
University of Texas Southwestern Medical School at Dallas, 1985
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
TX 119054801
Taxonomy
Federal specialty code 207N00000X (207N00000X)
Mailing address
325 Distel Cir, Los Altos, CA, 94022
NPI first listed
2006-03-18
NPI last updated
2020-01-08
NPI record certified
2020-01-08

This is when the NPI record was last certified, not a medical board exam.